Real-world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer.

ABSTRACT:

Background

BRAF mutation occurs in 5%-10% of metastatic colorectal cancers (mCRCs). Patients with BRAF mutant mCRC exhibit a specific metastatic pattern and poor prognosis. Survival outcomes are heterogeneous in cases of mCRC with a BRAF mutation. The optimal first-line therapy is still controversial.

Methods

We retrospectively reviewed the medical records of patients with mCRC between June 2010 and December 2021. Clinicopathologic characteristics, treatment and BRAF mutation testing results were collected. Patients with a BRAF mutation were included. Kaplan-Meier methods and log-rank tests were used to analyze and compare survival. Cox proportional hazards regression was used to establish the predictive nomogram model.

Results

Of the 4475 mCRC, 261 have a BRAF mutati

SUBMITTER: Xu T 

PROVIDER: S-EPMC10225206 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature